Hearing impairment is the most frequent sensory deficit in humans. It affects more than 250 million people worldwide and has a broad impact on quality of life. Not only does it limit the ability to interpret speech sounds leading to delayed language acquisition in children and reducing the ability of hearing-impaired adults to communicate, but hearing impairment also leads to economic and educational disadvantage, social isolation and stigmatization. Dramatic progress has been made in our understanding of hearing impairment through the mapping of more than 170 loci for non-syndromic hearing loss and the identification of more than 90 associated genes. Scientists in the MORL have cloned or collaborated in the identification of more than 20% of these genes and are exploring new ways to treat hearing loss.
- Hela Azaiez - Age-related hearing loss, noise-induced hearing loss, Mendelian hearing loss, genetic modifiers, promoters
- Ann Black-Ziegelbein - Bioinformatics, haplotyping, phasing
- Yoichiro Iwasa - Gene therapy for hearing loss and the molecular biology in noise exposed
- Jin-Young Koh - Role of pendrin and cellular mechanisms in SLC26A4-related hearing loss.
- Ryotaro Omichi - Gene therapy for hearing loss and the molecular biology in noise exposed mice.
- Mallory Tollefson - Molecular modeling of variants of uncertain significance in deafness-causing gene
- Monique Weaver - Gene therapy in OTOF knockout mice and genetic modifiers to alter the severity of TECTA-related hearing loss
Tremendous advances have been made in our understanding of the thrombotic microangiopathies (TMA) and it is now clear that distinctly different mechanisms underlie the pathophysiology of this group of diseases known previously as TTP/HUS (thrombotic thrombocytopenic purpura/hemolytic uremic syndrome). Establishing the role of complement in HUS has led to the development of anti-complement therapies that have improved patient outcome to such an extent that for children and adults with complement-mediated HUS (also known as atypical HUS or aHUS) long-term health is now a reality. Scientists in the MORL have contributed to this body of work in many ways and continue to focus on defining the different mechanisms that underlie aHUS to develop more refined diagnostic and treatment algorithms, resolve questions of phenotypic variability, and provide more precise patient care.
C3 Glomerulopathy (C3G) is the new designation for the group of glomerular diseases characterized by a dominant C3 immunofluorescence pattern on renal biopsy. Two major subgroups of C3G exist and are resolved by electron microscopy: Dense Deposit Disease (DDD) and C3 Glomerulonephritis (C3GN). Scientists in the MORL have made significant contributions to defining the genetic and acquired drivers of C3G and in defining the perturbations in the complement system that reflect disease activity. MORL scientists are also focused on developing new ways to treat C3G.
- Jill Hauer - Genetic variation in the glycomatrix in C3G; acquired drivers of disease in C3G
- Bertha Martin - Characterizing biomarkers in complement mediated renal diseases including Dense Deposit Disease and C3 Glomerulonephritis.
- Sofiya Pisarenka - Complement regulation at the glycomatrix (glycocalyx and GBM)
- Gabriella Pitcher - Functional consequences of a CFB variant in atypical hemolytic uremic syndrome (aHUS)
- Yuzhou Zhang - Complement dysregulation; complement functional assays; complement profiling
If you are interested in being a part of our hearing loss or kidney disease studies please contact Dr. Richard Smith, director of the MORL at:
Richard JH Smith - Director
200 Hawkins Drive - 21151 PFP
The University of Iowa
Iowa City, IA 52242